Gynecology: Menopause and Climacterium

Gynecology and Obstetrics · Clinical Specialties

How it begins

The climacteric transition represents the most profound endocrine reorganization of female adult life: the progressive depletion of the ovarian follicular reserve triggers sustained hypoestrogenism with vasomotor, genitourinary, bone, cardiovascular and neuropsychiatric repercussions that require an individualized approach, based on evidence and free of obsolete paradigms.

What it covers

1. · Fundamental Definitions
2. · The STRAW+10 System (Stages of Reproductive Aging Workshop)
3. · Follicular Depletion: The Irreversible Biological Clock
4. · Sequence of Hormonal Changes
5. · The Role of Adipose Tissue and Androgens
6. · Diagnosis is Fundamentally Clinical
7. · Differential Diagnosis of Perimenopausal Amenorrhea
8. · Comprehensive Evaluation in the Climacteric Consultation
9. · Pathophysiology: Dysfunction of KNDy Neurons
10. · Fezolinetant: NK3 Targeting as a Non-Hormonal Therapeutic Advance
11. · Stepped Management of Vasomotor Symptoms
12. · Clinical impact of vasomotor symptoms
13. · Pathophysiology
14. · Clinical Spectrum
15. · GMS Treatment
16. · The RANK-RANKL-OPG Axis and Accelerated Bone Loss
17. · Diagnosis of Osteoporosis
18. · Therapeutic Strategies
19. · The "Timing Hypothesis"
20. · The Window of Perimenopausal Emotional Vulnerability
21. · Subjective Cognitive Complaints ("Brain Fog")
22. · Sleep Disorders
23. · Fundamental Principle: Need for Progestin with an Intact Uterus
24. · Routes of Administration: Relevance of the First Hepatic Pass
25. · Progestin Regimens
26. · Types of Progestin: Relevance of the Safety Profile
27. · Approved THM Indications
28. · The Women's Health Initiative (WHI): Findings and Reinterpretation
29. · Quantification of Specific Risks
30. · Absolute Contraindications of Systemic MHT
31. · Hypoactive Sexual Desire Disorder (HSDD) and Testosterone Therapy
32. · Comprehensive Approach
33. · Definition and Diagnosis
34. · Etiology
35. · Management: THM is Not Optional
36. · Surgical Menopause: Greater Symptomatic Intensity
37. · Risk Reducing Salpingoophorectomy (RRSO) in BRCA1/2 Carriers
38. · Chemotherapy-Induced Ovarian Failure
39. · Management of Menopause in Survivors of Hormone-Dependent Breast Cancer
40. · Periodic Health Assessment in Postmenopause
41. · Lifestyle Interventions with Greater Evidence Support
42. · Continuous reevaluation of the THM
43. · A comprehensive vision of the health of mature women